Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Thymic Cancer
Reports on thymic cancer findings from X.F. Li and co-researchers provide new insights
July 6th, 2009
According to recent research published in the journal Medical Oncology, "Platinum-based chemotherapy regimens are often recommended for patients with unresectable thymic carcinoma. In more than 60 cases, however, the systemic chemotherapy provides little benefit." "In this report, we described a case of advanced KIT- and VEGF-positive thymic carcinoma with liver and lung metastasis. The patient, a 46-year-old man, exhibited a resistance to cisplatin-based chemotherapy, but responded to the treatment with sorafenib, a molecular target-based therapy. After 4 months of sorafenib therapy, his lung and liver metastases as well as the mediastinal tumor shrank...
Source: Biotech Business Week (2009-07-06)
|
